Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of Estrogen Receptor 1 (ESR1) Mutations in (Human Epidermal Growth Factor Receptor) HR+/HER2- Metastatic Breast Cancer (MBC)
2026. nov. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.
2026. okt. 31.· Future oncology (London, England)· PUBMED
Publikáció
Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer.
2026. okt. 13.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Development of a clinical-grade ultrasensitive droplet digital PCR test for monitoring of relevant ESR1 variants by liquid biopsy.
2026. okt. 13.· The journal of liquid biopsy· PUBMED
Publikáció
Hyodeoxycholic acid rejuvenates BMSCs against postmenopausal osteoporosis by attenuating senescence and aberrant adipogenesis via TGR5-ESR1-mediated mitophagy.
2026. okt. 10.· Journal of advanced research· PUBMED
Publikáció
AMCP Market Insights: Managed care approaches to ESR1-mutated advanced breast cancer.
2026. okt. 1.· Journal of managed care & specialty pharmacy· PUBMED
Publikáció
Identification and Validation of the ESR1 Y537S Mutant-Enriched Enhancer and Its Downstream Target IGFBP3.
2026. okt. 1.· Cancer research communications· PUBMED
Vizsgálat
SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC
2026. szept. 30.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
FDA adds vepdegestrant to options for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.
2026. szept. 15.· Cancer· PUBMED
Publikáció
Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting.
2026. szept. 14.· ESMO open· PUBMED
Publikáció
Real-world estrogen receptor alpha 1 (ESR1) testing patterns and results for ER+/HER2- metastatic breast cancer in the United States, 2018-2024.
2026. szept. 9.· Breast cancer research and treatment· PUBMED
Publikáció
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024.
2026. szept. 9.· Breast cancer research and treatment· PUBMED
Publikáció
Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2- Metastatic Breast Cancer.
2026. szept. 8.· Molecular diagnosis & therapy· PUBMED
Vizsgálat
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
2026. aug. 18.· PHASE2 · RECRUITING· CTGOV
Preprint
Extreme ESR1 Polyclonality, Mutation Dynamics, and Effects on Treatment Outcomes in Patients with ER+ Metastatic Breast Cancer.
2026. aug. 10.· Research square· PUBMED
Publikáció
Correlation between ESR1 mutation and PD-L1 expression in breast carcinoma: A narrative review.
2026. aug. 1.· Critical reviews in oncology/hematology· PUBMED
Publikáció
Dynamic circulating tumor DNA profiling of ESR1 mutations in HR+/HER2- advanced breast cancer: from prognostic biomarker to clinical decision-making - a comprehensive review.
2026. júl. 31.· Frontiers in oncology· PUBMED
Publikáció
ESR1 Y537S Detected in a Brain Metastasis but Not in Plasma ctDNA in HR+/HER2-Low Metastatic Breast Cancer: A Case Report.
2026. júl. 28.· Current oncology (Toronto, Ont.)· PUBMED
Publikáció
ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6.
2026. júl. 23.· Journal of immunotherapy and precision oncology· PUBMED
Publikáció
Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer.
2026. júl. 17.· Frontiers in pharmacology· PUBMED
Publikáció
[Imlunestrant - ER+/HER2-, locally advanced or metastatic breast cancer with an activating ESR1 mutation].
2026. júl. 15.· Bulletin du cancer· PUBMED
Publikáció
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
2026. júl. 13.· The Lancet. Oncology· PUBMED
Publikáció
Cancer-related microangiopathic hemolytic anemia (CR-MAHA) in a metastatic breast cancer patient with a germ-line ATM single nucleotide variant and an ESR1 fusion variant: insights from a case report on early diagnosis and improved outcomes.
2026. júl. 7.· Frontiers in oncology· PUBMED
Publikáció
Endothelial estrogen receptor alpha (ESR1) regulates cerebral cavernous malformation pathogenesis via MEKK3-KLF signaling pathway.
2026. júl. 6.· Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism· PUBMED
Publikáció
ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer.
2026. júl. 3.· The journal of liquid biopsy· PUBMED
Publikáció
ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance.
2026. jún. 27.· Genome medicine· PUBMED
Publikáció
The ESR1-MYH14 axis functions as a critical driver of cervical cancer progression and metastasis.
2026. jún. 25.· Translational oncology· PUBMED
Publikáció
A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy.
2026. jún. 24.· Cancers· PUBMED
Vizsgálat
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
2026. jún. 19.· NA · RECRUITING· CTGOV
Publikáció
A Plant-Derived Flavonoid, Isobavachin, Promotes Osteogenesis and Alleviates Glucocorticoid-Induced Osteoporosis via Modulation of the ESR1-PI3K/Akt Signaling Pathway.
2026. jún. 18.· Molecules (Basel, Switzerland)· PUBMED